Embera NeuroTherapeutics to Present at the 10th Annual Biotech Showcase

BOSTON, Mass. and SHREVEPORT, La. – July, 26, 2016 – December 12, 2017 – Embera NeuroTherapeutics, Inc., a specialty pharmaceutical company developing novel treatments for cocaine, nicotine, and other addictions, today announced that Robert (Bob) Linke, the Company’s President and Chief Executive Officer, and Michael Detke, M.D., Ph.D., the Company’s Chief Medical Officer, will present at the 10th Annual Biotech Showcase on Monday, January 8, 2018 at 10:00 a.m. Pacific time. The conference is being held from January 8-10, 2018 at the Hilton San Francisco Union Square in San Francisco, California.

“Embera has a tremendous opportunity to further the development of EMB-001 into Phase 2 clinical trials in cocaine use disorder and tobacco use disorder. We are pleased with the opportunity to present at the Biotech Showcase to educate new audiences about our company and our lead candidate EMB-001 and its novel approach to addressing stress mediated diseases,” said Bob Linke.

About Embera NeuroTherapeutics
Embera NeuroTherapeutics, Inc. is a clinical-stage pharmaceutical company focused on stress modulation as an innovative way of treating a broad range of addictions and other diseases where there are significant public health impacts and a very limited range of effective therapies. Embera is developing a novel drug combination (EMB-001) targeting specific brain functions related to stress responses that drive craving and relapse associated with these disorders. Embera is advancing EMB-001 development programs in cocaine use disorder and smoking cessation. www.emberaneuro.com


Bob Linke President and CEO
Embera NeuroTherapeutics, Inc.
[email protected]

For Media:
MacDougall Biomedical Communications
Kari Watson or Kara Mazey, 781-235-3060
[email protected]
[email protected]